In this article, we will discuss the 10 Stocks under $10 that will triple.
As we delve into the discussion on stocks that will triple, we must shed light on the U.S. small-cap stocks, which are struggling amid broader market challenges due to ongoing shifts in tariff policy, affecting investors’ confidence. The Russell index (which tracks small-cap stocks) has fallen over 15% from its peak in November 2024 as of the time of writing this article and is down by nearly 19% on a YTD basis. However, the broader market, mostly consisting of large-cap stocks, has only dropped about 14% on a YTD basis. This gap shows how economic uncertainties and higher interest rates have more impact on smaller companies as they typically carry more debt and feel borrowing costs more acutely.
Furthermore, trade tensions have added to small-cap stocks’ volatility. Reuters reported that Trump’s new 25% tariffs on Canadian, Mexican, and Chinese imports rolled out on March 4, with more duties to be imposed by April 2. This measure affects nearly $2.2 trillion in trade and has sparked retaliatory tariffs from Canada and China, which have stoked inflation fears and triggered global market drops. As such, small-cap companies with international supply chains now face higher costs that could damage their profitability.
Yet, small-cap stocks might bounce back as Trump’s domestic economic growth agenda could benefit these U.S.-based companies. In addition, onshoring and increased capital expenditures (CAPEX) might boost the sector’s earnings. Furthermore, analysts believe that stabilizing inflation and easing interest rates could help small-caps recover in the second half of 2025.
As such, inflation seems to be leveling off, which is beneficial for small-cap companies. While high rates have pressured these debt-reliant companies, the Federal Reserve’s decision to slow rate hikes in late 2024 provided some breathing room. With inflation settling between 1% and 3%—historically complimentary for small-caps—the sector’s performance is expected to get a boost. Therefore, as financial market trends are settling, analysts expect small-cap earnings to outpace large-cap in 2025, especially later in the year.
A significant move that could be helpful for small-cap stocks is the recovery in mergers and acquisitions (M&A) and initial public offerings (IPOs). Even though deal activity slowed during recession fears, M&A rebounded in 2024 and is expected to continue in 2025. Historically, rising M&A activity has boosted returns across market caps and proven to be beneficial for small-caps, as it makes those companies acquisition targets, increasing investors’ interest.
Moreover, industry changes and technological advances offer more opportunities to small-cap companies. While the AI boom has mostly helped mega-cap tech industries, many smaller companies are crucial to AI infrastructure in terms of cybersecurity and thermal management. A 2023 PwC report valued the healthcare AI market at $11 billion, projecting its growth to $188 billion by 2030.
Despite the market challenges, some small-caps under $10 have beaten the broader market, showing resilience amid inflation and trade uncertainties. They show remarkable growth possibilities even as conditions fluctuate. Thus, the position of small-cap stocks looks strong, which is why we will now look at the 10 stocks under $10 that will triple.
Aerial view of a skyscraper contrasted against the rising sun.
Methodology
We chose consensus picks of credible websites and compiled a list of stocks priced at $10 or less that are expected to triple. Furthermore, we used a screener to identify stocks with a projected upside potential of over 300%. We have also assessed the hedge fund sentiment from Insider Monkey’s database of over 1,000 elite hedge funds tracked as of the end of the fourth quarter of 2024. The list is arranged in ascending order of the number of hedge fund holders in each stock.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10. ImmunityBio, Inc. (NASDAQ:IBRX)
Upside Potential: 305.36%
Number Of Hedge Funds: 15
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotech company developing immune-enhancing therapies for cancer and infectious diseases. It uses cutting-edge platforms like cytokine fusion proteins and cell therapies. The company has moved nine first-in-human treatments into clinical trials for solid and liquid tumors.
For the fourth quarter of 2024, revenue hit $7.55 million, a huge jump from just $0.14 million a year earlier. Although this fell short of what analysts expected, the company’s quarterly loss narrowed to $0.15 per share, better than the $0.19 per share loss in Q4 2023. As such, ImmunityBio, Inc. (NASDAQ:IBRX) has beaten predicted earnings in two of the last four quarters, showing improved financial health.
ImmunityBio, Inc. (NASDAQ:IBRX) is growing its footprint globally with key regulatory wins. The European Medicines Agency accepted the company’s application for ANKTIVA, a crucial step toward potential approval in 30 countries. This follows the company’s previous submission to the UK’s Medicines and Healthcare Products Regulatory Agency. Moreover, the company also got a permanent J-code for ANKTIVA starting January 2025, making insurance claims easier and expanding U.S. patient access.
With its improving financials and regulatory approvals, ImmunityBio (NASDAQ:IBRX) stands out among stocks that will triple. It has scaled production well, with over 125,000 ANKTIVA doses available, which now have a three-year shelf life, ensuring supply for both sales and trials. As it expands globally and advances its pipeline, ImmunityBio offers strong growth potential for biotech investors. As such, it is one of the stocks that will triple.
9. Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Upside Potential: 333.88%
Number Of Hedge Funds: 31
Intellia Therapeutics, Inc. (NASDAQ:NTLA) develops gene-editing treatments for genetic diseases. Its main programs include NTLA-2001 for transthyretin amyloidosis (a heart and nerve disorder) and NTLA-2002 for hereditary angioedema (a rare swelling condition). The company is also creating cancer and autoimmune therapies through partnerships.
For Q4 that ended December 31, 2024, Intellia Therapeutics, Inc. (NASDAQ:NTLA) reported that revenue jumped to $12.9 million from negative $1.9 million in 2023, mainly from its Regeneron partnership. R&D costs rose to $116.9 million as it invested in key programs, whereas G&A costs increased to $32.4 million. As such, the company ended the year with $861.7 million in cash and securities, down from $1 billion in 2023, funding its late-stage clinical work.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) continues its Phase III HAELO study for NTLA-2002 for hereditary angioedema, with enrollment expected to finish in late 2025. Nex-Z, formerly named NTLA-2001, is progressing through Phase III trials for ATTR amyloidosis with the MAGNITUDE cardiomyopathy study aiming to enroll over 550 heart patients by the end of the year. Recent Phase I data showed Nex-Z creating deep, lasting TTR reductions, suggesting it could significantly slow disease progression.
Furthermore, Intellia Therapeutics (NASDAQ:NTLA) plans to file BLAs between 2026-2028, targeting product launches from 2027-2030. Also, early 2025 brought a strategic shift, focusing on late-stage programs while dropping NTLA-3001. These changes should cut operating costs by 5-10% in 2025, saving money for commercialization.
Thus, with several advanced candidates, Intellia Therapeutics, Inc. (NASDAQ:NTLA) is set for major growth in gene editing, making it to our list of stocks that will triple.
